Clinical Trial Update: Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial assessing brain amyloid and vascular effects of eicosapentaenoic acid in Alzheimer's disease completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Eicosapentaenoic acid (eicosapentaenoic acid)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Alzheimer's Disease | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2024-11-26